BioVersys AG (XSWX:BIOV) Total Current Liabilities: CHF8.90 Mil (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.30
View Full Analysis

What is BioVersys AG Total Current Liabilities?

BioVersys AG XSWX:BIOV -2.59% 4 Total Current Liabilities is CHF8.90 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BioVersys AG's total current liabilities for the quarter that ended in Dec. 2025 was CHF8.90

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BioVersys AG Total Current Liabilities Related Terms

BioVersys AG Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Current Liabilities Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Current Liabilities
9.67 8.90

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Current Liabilities 0.00 9.67 10.21 8.90
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BioVersys AG's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.631+0.289
+Other Current Liabilities+Current Deferred Liabilities
=5.976+0
=8.90

BioVersys AG's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=2.631+0.289
+Other Current Liabilities+Current Deferred Liabilities
=5.976+0
=8.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of CHF8.90 Mil mean?
BioVersys AG (XSWX:BIOV) has a Total Current Liabilities of CHF8.90 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Total Current Liabilities too high?
BioVersys AG's current Total Current Liabilities is CHF8.90 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Current Liabilities compare to VRTX and REGN?
BioVersys AG's Total Current Liabilities of CHF8.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors. BioVersys AG's current Total Current Liabilities is CHF8.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Current Liabilities of CHF8.90 Mil. The current Total Current Liabilities is CHF8.90 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Current Liabilities is CHF8.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price